Trial Profile
Analysis of hepatitis C viral kinetics and viramidine [taribavirin] pharmacokinetics utilizing two treatment regimens in therapy-naive patients with chronic hepatitis C
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Taribavirin (Primary) ; Peginterferon alfa-2b
- Indications Hepatitis C
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Bausch Health Companies
- 21 Jun 2012 Additional lead trial investigator (Doyle RT) added as reported by ClinicalTrials.gov.
- 03 Mar 2008 Planned end date 1 May 2007 added as reported by ClinicalTrials.gov.
- 03 Mar 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.